Evidence map›Paper›PMID 36225650›Full record

ArticleNeuro-oncology advances

Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing.

Chao Li, Zhong Liu, Xiaoxia Zhang, Huafeng Wang, Gregory K Friedman, Qiang Ding, Xinyang Zhao, Hu Li, Kitai Kim, Xi Yu and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Chao LiDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL 35294, USA.
Zhong LiuDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL 35294, USA.
Xiaoxia ZhangDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL 35294, USA.
Huafeng WangDepartment of Neurology, University of Alabama at Birmingham, AL 35294, USA.
Gregory K FriedmanDepartment of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Qiang DingDepartment of Anesthesiology and Perioperative Medicine & Molecular and Translational Biomedicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xinyang ZhaoDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL 35294, USA.
Hu LiDepartment of Molecular Pharmacology & Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55904, USA.
Kitai KimHuman Stem Cell & Genome Engineering Center and Department of Biological Chemistry, University of California, Los Angeles, CA 90095, USA.
Xi YuClinical Oncology Center, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China.
L Burt NaborsDepartment of Neurology, University of Alabama at Birmingham, AL 35294, USA.
Xiaosi HanDepartment of Neurology, University of Alabama at Birmingham, AL 35294, USA.
Rui ZhaoDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, AL 35294, USA.ORCID https://orcid.org/0000-0003-3769-6550
University of Alabama at Birmingham · USMayo Clinic · USThe People's Hospital of Guangxi Zhuang Autonomous Region · CNUniversity of California, Los Angeles · US

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI David M. Bedwell · 2007 to 2026
$23.0M
NWASP regulates neuroinflammation and cognition in Alzheimer's diseaseR01HL143017 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DING, QIANG, PITTET, JEAN-FRANCOIS · 2018 to 2021
$2.2M
The Impaired FRNK in IPFR01HL152183 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DING, QIANG · 2021 to 2024
$2.2M
Explore the APOE e4-mediated p53 activation in Alzheimer's DiseaseR01OD026594 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, WEI, ZHAO, RUI · 2019 to 2022
$1.7M
Modeling low-grade gliomas using human pluripotent stem cellsR21NS106430 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HAN, XIAOSI, ZHAO, RUI · 2018 to 2019
$408k
NHLBI NIH HHS R01 HL143017NHLBI NIH HHS R01 HL152183NIDDK NIH HHS P30 DK072482NIH HHS R01 OD026594NINDS NIH HHS R21 NS106430
6 · The paper itself

Abstract

Background: Chromosomal translocation has been detected in many human cancers including gliomas and is considered a driving force in tumorigenesis. Co-deletion of chromosome arms 1p and 19q is a hallmark for oligodendrogliomas. On the molecular level, 1p/19q co-deletion results from t(1;19)(q10;p10), which leads to the concomitant formation of a hybrid chromosome containing the 1q and 19p arms. A method to generate 1p/19q co-deletion is lacking, which hinders the investigation of how 1p/19q co-deletion contributes to gliomagenesis. Methods: We hypothesized that chromosomal translocation, such as t(1;19)(q10;p10) resulting in the 1p/19q co-deletion, may be induced by simultaneously introducing DNA double-strand breaks (DSBs) into chromosomes 1p and 19q using CRISPR/Cas9. We developed a CRISPR/Cas9-based strategy to induce t(1;19)(q10;p10) and droplet digital PCR (ddPCR) assays to detect the hybrid 1q/19p and 1p/19q chromosomes. Results: After translocation induction, we detected both 1p/19q and 1q/19p hybrid chromosomes by PCR amplification of the junction regions in HEK 293T, and U-251 and LN-229 glioblastoma cells. Sequencing analyses of the PCR products confirmed DNA sequences matching both chromosomes 1 and 19. Furthermore, the 1p/19q hybrid chromosome was rapidly lost in all tested cell lines. The 1q/19p hybrid chromosome also become undetectable over time likely due to cell survival disadvantage. Conclusion: We demonstrated that t(1;19)(q10;p10) may be induced by CRISPR/Cas9-mediated genomic editing. This method represents an important step toward engineering the 1p/19q co-deletion to model oligodendrogliomas. This method may also be generalizable to engineering other cancer-relevant translocations, which may facilitate the understanding of translocation roles in cancer progression.

Indexed as

1p/19q co-deletionchromosome translocationCRISPR/Cas9IDH mutant low-grade gliomasoligodendroglioma

Identifiers

PMID36225650
PMCPMC9547542
OpenAlexW4292249798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.